Stockscreener 앱 받기
2.32
7.94%
-0.20
시간 외 거래:
2.32
Nrx Pharmaceuticals Inc 주식(NRXP)의 최신 뉴스
$3 Billion Suicidal Depression Market May Soon be Accessible via - openPR.com
$3 Billion Suicidal Depression Market May Soon be Accessible via FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025 - GlobeNewswire
NRx Pharmaceuticals stock price target raised to $21 by BTIG on FDA progress - Investing.com India
FDA Grants NRX-100 for Suicidal Ideation the Fast Track Designation - HCPLive
FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients With Depression, Including Bipolar Depression - Psychiatric Times
FDA grants fast track designation for NRx’s depression treatment By Investing.com - Investing.com Australia
New to The Street Client NRx Pharmaceuticals (NASDAQ:NRXP) Secures FDA Fast Track Designation for NRX-100, Expanding Reach to 13 Million Americans Confronting Suicidal Ideation - ACCESS Newswire
Nrx Pharmaceuticals shares rise 3.17% premarket after FDA granted designation for NRX-100, expanding addressable population. - AInvest
NRx Pharma Receives FDA Fast Track Designation for NRX-100 for Treating Suicidal Ideation in Depression - AInvest
FDA grants fast track designation to NRx for suicidal ideation drug - Investing.com
NRX Pharmaceuticals: D. Boral Capital maintains Buy, PT raised to $31. - AInvest
NRx Pharmaceuticals and the Regulatory Catalysts Reshaping Mental Health Innovation - AInvest
FDA grants NRX-100 "unmet need" designation for treating 13 million Americans with suicidal thoughts. - AInvest
NRx Pharmaceuticals Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression Patients - AInvest
FDA Fast Track Breakthrough: NRX-100 Shows 63% Success Rate in Suicidal Depression Treatment - Stock Titan
NRX Pharmaceuticals WRT NRXPW 2025Q2 Earnings Preview Upside Potential on New Product Launch - AInvest
NRX Pharmaceuticals NRXP 2025Q2 Earnings Preview Upside Potential Driven by New Product Launch - AInvest
Is a relief rally coming for NRx Pharmaceuticals Inc. Equity Warrant holdersSmart Stock Forecast Using AI Algorithms - Newser
NRx Pharmaceuticals Inc. stock trend outlook and recovery pathReal Chart Based Opportunity Identification - Newser
Using R and stats models for NRx Pharmaceuticals Inc. forecastingFree Breakout Confirmation With Entry Tracker - Newser
How to recover losses in NRx Pharmaceuticals Inc. Equity Warrant stockAI Stock Movement Forecast with Accuracy - Newser
Can machine learning forecast NRx Pharmaceuticals Inc. recoveryShort-Term Price Breakout Signal Analysis - Newser
Key metrics from NRx Pharmaceuticals Inc.’s quarterly dataPredictable Return Strategy with AI Support - Newser
Combining machine learning predictions for NRx Pharmaceuticals Inc. Equity WarrantGrowth Watchlist for Long Term Positioning - Newser
What machine learning models say about NRx Pharmaceuticals Inc. Equity WarrantFree Smart Trend Trading with Weekly Signals - Newser
Is NRx Pharmaceuticals Inc. stock bottoming outFree Risk Controlled Short Term Trade Plans - Newser
Relative strength of NRx Pharmaceuticals Inc. Equity Warrant in sector analysisTechnical Safety Zone Pattern Recognition - Newser
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals - ACCESS Newswire
NRx Pharmaceuticals Receives Final Approval to Acquire Dura Medical, Enhancing Mental Health Services in Florida - AInvest
New Product Launches: Will They Boost NRx Pharmaceuticals Inc. Equity Warrant Stock in 2025Capital Safe Picks with Consistent Gains - Newser
Key resistance and support levels for NRx Pharmaceuticals Inc. Equity WarrantBuy Entry Confirmation Based on Technical Analysis - Newser
Trend analysis for NRx Pharmaceuticals Inc. this weekGrowth Summary Based on Market Positioning - Newser
Can NRx Pharmaceuticals Inc. recover in the next quarterTechnical Insight Guide for Safer Trades - Newser
Multi factor analysis applied to NRx Pharmaceuticals Inc. Equity WarrantBuy Point Strategy with Profit Protection - Newser
Is NRx Pharmaceuticals Inc. showing signs of accumulationFast Movement Forecast for Trading Success - Newser
Technical analysis overview for NRx Pharmaceuticals Inc. stockEntry Optimization Guide with Volume Analysis - Newser
Applying chart zones and confluence areas to NRx Pharmaceuticals Inc.Expert-Backed High Yield Stock Watchlist - Newser
NRx Pharmaceuticals Inc. Equity Warrant Company’s Quarterly Earnings Growth: What the Numbers SayFree Smart Money Tracking Signal Generator - Newser
Nrx Pharmaceuticals shares rise 1.19% after-hours following AHCA approval for Dura Medical acquisition. - AInvest
NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics(TM) Secures Florida Regulatory Clearance to Close Dura Medical Acquisition - ADVFN Brasil
HOPE Therapeutics receives Florida approval for Dura Medical acquisition By Investing.com - Investing.com Nigeria
NRx Secures Florida Approval to Acquire Veterans Mental Health Provider Dura Medical - Stock Titan
New to The Street Show #682 Premieres on Bloomberg Tonight Featuring Industry Leaders: DataVault, PetVivo, Health In Tech, FLOKI, and NRx Pharma Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustai - Foster's Daily Democrat
Forecasting NRx Pharmaceuticals Inc. price range with options dataFree Trade Scanner With Buy Zone Alerts - Newser
NRx Pharmaceuticals Inc. stock chart pattern explainedFree Swing Trading Entry Point Signals - Newser
Statistical indicators supporting NRx Pharmaceuticals Inc.’s strengthMomentum Entry Alerts with Risk Control - Newser
NRX Pharmaceuticals Maintains 'Buy' Rating with $31.00 Price Target - AInvest
Actions to Remove Benzethonium Chloride from Ketamine Products in Favor of Safer and Superior Option in $750 Million Market, Projected to Reach $3.35 Billion by 2034: NRx Pharmaceuticals, Inc. - Barchart.com
NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
1.02%
3.70%
자본화:
|
볼륨(24시간):